Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cue Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, DEC. 19, 2025 (GLOBE NEWSWIRE) -- CUE BIOPHARMA, INC. (NASDAQ: CUE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL CLASS OF THERAPEUTIC BIOLOGICS TO SELECTIVELY ENGAGE AND MODULATE DISEASE-SPECIFIC T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASE, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 35,714,286 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN LIEU THEREOF) AND ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE AN AGGREGATE OF 17,857,143 SHARES OF COMMON STOCK. EACH SHARE OF COMMON STOCK (OR PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IN LIEU THEREOF) AND ACCOMPANYING COMMON STOCK WARRANT ARE BEING SOLD TOGETHER AT A COMBINED PUBLIC OFFERING PRICE OF $0.28 (OR $0.279, IN THE CASE OF PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK). THE AGGREGATE GROSS PROCEEDS OF THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $10 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. EACH COMMON STOCK WARRANT WILL HAVE AN EXERCISE PRICE OF $0.30 PER SHARE, WILL BE EXERCISABLE IMMEDIATELY AND WILL EXPIRE FIVE YEARS FROM THE DATE OF ISSUANCE. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT DECEMBER 22, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. IN ADDITION, CUE BIOPHARMA HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 5,357,140 SHARES OF ITS COMMON STOCK AND/OR WARRANTS TO PURCHASE UP TO 2,678,570 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SECURITIES ARE BEING OFFERED BY CUE BIOPHARMA.

CUE BIOPHARMA ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING

BOSTON, DEC. 18, 2025 (GLOBE NEWSWIRE) -- CUE BIOPHARMA, INC. (NASDAQ: CUE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL CLASS OF THERAPEUTIC BIOLOGICS TO SELECTIVELY ENGAGE AND MODULATE DISEASE-SPECIFIC T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT IT IS COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS TO PURCHASE COMMON STOCK IN LIEU THEREOF) AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF COMMON STOCK. IN ADDITION, CUE BIOPHARMA INTENDS TO GRANT THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK AND/OR WARRANTS TO PURCHASE SHARES OF COMMON STOCK OFFERED IN THE PUBLIC OFFERING. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING. ALL OF THE SECURITIES ARE BEING OFFERED BY CUE BIOPHARMA.

CUE BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING

ANNOUNCED STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH IMMUNOSCAPE TO DEVELOP BREAKTHROUGH CELL THERAPY APPROACH FOR SOLID TUMORS  COMPANY IS ENTITLED TO RECEIVE UPFRONT PAYMENTS TOTALING $15M ANNOUNCED STRATEGIC TRANSITION IN LEADERSHIP TO FURTHER ENABLE NEXT STAGE OF GROWTH WITH DISRUPTIVE AUTOIMMUNE THERAPEUTIC CANDIDATES, MOST NOTABLY CUE-401, THE COMPANY'S LEAD AUTOIMMUNE ASSET BOSTON, NOV. 12, 2025 (GLOBE NEWSWIRE) -- CUE BIOPHARMA, INC.(NASDAQ: CUE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL CLASS OF THERAPEUTIC BIOLOGICS TO SELECTIVELY ENGAGE AND MODULATE DISEASE-SPECIFIC T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASE AND CANCER, TODAY PROVIDED A BUSINESS AND FINANCIAL UPDATE FOR THE THIRD QUARTER 2025. DURING THE THIRD QUARTER OF 2025 AND EARLY IN THE FOURTH QUARTER, THE COMPANY MADE TREMENDOUS PROGRESS FROM HAVING SUCCESSFULLY IMPLEMENTED A PLAN OF OPTIONALITY AND LAYING THE NECESSARY GROUNDWORK FOR FUTURE GROWTH, SAID USMAN AZAM, M.D.

CUE BIOPHARMAREPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT FOCUSES ON ADVANCING NOVEL T CELL THERAPY SEED-AND-BOOST APPROACH EXPLOITING THE MECHANISM OF THE CUE-100 SERIES OF IMMUNO-STATS NOVEL THERAPEUTIC APPROACH IS DESIGNED TO ENABLE IN VIVO EXPANSION AND ACTIVATION OF INFUSED T CELL RECEPTOR ENGINEERED T CELLS (TCR-TS) TO PROVIDE DURABILITY, TOLERABILITY AND ENHANCED CLINICAL BENEFIT WHILE REDUCING MANUFACTURING COMPLEXITY COMPELLING DATA GENERATED IN PRECLINICAL MODELS OF MULTIPLE SOLID TUMORS, INCLUDING PANCREATIC AND OVARIAN, DEMONSTRATES THE CLINICAL POTENTIAL OF THIS NOVEL IMMUNOTHERAPY APPROACH WITH IND-ENABLING STUDIES ON TRACK FOR 2027 SUBMISSION BOSTON AND SINGAPORE, NOV. 06, 2025 (GLOBE NEWSWIRE) -- CUE BIOPHARMA, INC.(NASDAQ: CUE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL CLASS OF THERAPEUTIC BIOLOGICS TO SELECTIVELY ENGAGE AND MODULATE DISEASE-SPECIFIC T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASE AND CANCER, AND IMMUNOSCAPE, PTE. LTD, A BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION T CELL RECEPTOR (TCR)-BASED THERAPIES IN ONCOLOGY, TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A COLLABORATION AND LICENSE AGREEMENT TO ADVANCE A NOVEL IN VIVO APPROACH TO CELL THERAPY FOR THE TREATMENT OF SOLID TUMORS.

Cue Biopharma, Inc.

CUE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cue Biopharma, Inc.

CUE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CUE